Our Pipeline:
Stream Neuroscience Innovation
Selective targeting of essential signaling molecules deep inside the cell
Promising Clinical Candidates
SN-2000
MitoREAD revealed that inhibition of phosphodiesterase 4B (PDE4B) can reduce the frequency of seizures in animal models of epilepsy and improve cognition in the aging brain. SN-2000 works by increasing levels of cyclic adenosine monophosphate (cAMP), a crucial signaling molecule that helps regulate neuronal activity and communication. By boosting cAMP levels, PDE4 inhibitors can stabilize neuronal balance and make them less prone to seizures. Additionally, enhanced cAMP levels can promote improved efficiency and connectivity in the brain, that will support cognitive functions such as learning, memory, and problem-solving. SN-2000 offers a new mechanism of action for treating both epilepsy and cognitive decline.
Phosphoinositide 3-kinase (PI3K) Discovery Program
The PI3K pathway is vital for cell growth, survival, and metabolism, and its dysregulation can lead to abnormal neuronal activity and cognitive impairments. By inhibiting PI3K, Stream Neuroscience hopes to reduce excessive signaling that contributes to epileptic seizures, thereby helping to stabilize neuronal activity and decrease seizure frequency. Additionally, PI3K inhibitors can promote neuroprotective effects, safeguarding neurons from damage and supporting their health. This stabilization of neuronal function can also enhance neural synchrony, enabling the brain to form new connections and improve cognitive abilities such as memory, learning, and higher cognitive functions. Stream Neuroscience’s PI3K drug discovery program hold promise as a therapeutic strategy to manage epilepsy and cognitive disorders by ensuring that neuronal signaling remains balanced and effective.
